Resources
34 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/19/2024
Researchers assessed whether there was a connection between buprenorphine dose and time to treatment discontinuation when fentanyl is prevalent. The results showed that a 24mg dose of buprenorphine remained in treatment longer than those prescribed 16mg. Therefore, higher buprenorphine doses could be considered to help improve treatment retention.
Posted 4/12/2024
These documents from the South Southwest MHTTC provide information about Peer Specialists in crisis settings.
Posted 5/19/2021 (updated 4/10/2024)
CA Bridge, a program of the Public Health Institute, works to ensure that all people with substance use
disorder receive 24/7 access to high-quality care in every California health system. Addiction treatment
should be part of standard medical practice in the emergency department and inpatient settings in order
to increase treatment access and save lives.
Posted 5/17/2021 (updated 4/10/2024)
New medications for office-based treatment of opioid
addiction are comparable in efficacy to other chronic
conditions such as diabetes, asthma, and hypertension
when combined with other interventions and as part of a
comprehensive care plan. They are safe, highly effective,
can be prescribed and/or administered at the Community
Health Center, with a sustainable business plan.
Posted 4/26/2021 (updated 4/10/2024)
A Protocol Using Empirically Supported Behavioral Treatments for People with Psychoactive Stimulant Use Disorders
Posted 4/26/2021 (updated 4/10/2024)
The Evidence-Based Resource Guide Series is a comprehensive set of modules with resources to improve health outcomes for people at risk for, with, or recovering from mental and/or substance use disorders. It is designed for practitioners, administrators, community leaders, and others considering an intervention for their organization or community.
Posted 4/5/2024
This study assessed the associations between insurance status and 6-month retention of patients with opioid use disorder on telehealth platforms. Patients whose insurance paid for their care were most likely to still be receiving buprenorphine 6 months after starting treatment. Uninsured patients who paid cash were more likely to be in treatment at 6 months than people with insurance that did not cover their care. Findings showed an association between in-network insurance benefits and retention, which may affect the opioid crisis.
Posted 1/5/2021 (updated 4/4/2024)
Bringing Recovery Supports to Scale Technical Assistance Center Strategy (BRSS TACS) created this directory based on information obtained from state certification boards for alcohol and substance use professionals, state mental health and substance use disorder authorities, sources identified by the International Certification & Reciprocity Consortium (IC&RC), local and statewide recovery community organizations, and the National Association of State Alcohol and Drug Abuse Directors. The information sources for each state are noted. All italicized text is a direct quote from the source noted. The information in this directory was current as of June 24, 2020.
Posted 12/9/2020 (updated 4/3/2024)
Detailed risk benefit assessment of medications, settings and patient outcomes. These guidelines were developed in response to a resolution from the United Nations Economic and Social Council (ECOSOC), “to develop and publish minimum requirements and international guidelines on psychosocially assisted pharmacological treatment of persons dependent on opioids”
Posted 12/9/2020 (updated 4/3/2024)
State policymakers are interested in learning about the most effective treatments to address OUD and avoid unintended consequences such as overdose events, mortality from overdose, and use of illicit and unregulated drugs. This article describes the lack of evidence surrounding the use of Medically Supervised Withdrawal as a standalone “treatment.”